Drugs / MK-7252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03326986 | Nov 2017 → Dec 2018 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03326986 ↗ |
| Route | Oral | “powder for oral suspension administered with a water volume” NCT03326986 ↗ |